# Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

> **NCT01198626** · PHASE2 · TERMINATED · sponsor: **Furiex Pharmaceuticals, Inc** · enrollment: 32 (actual)

## Conditions studied

- Community-Acquired Bacterial Pneumonia (CABP)

## Interventions

- **DRUG:** JNJ-32729463
- **DRUG:** moxifloxacin
- **DRUG:** JNJ-32729463 (Open-Label)

## Key facts

- **NCT ID:** NCT01198626
- **Lead sponsor:** Furiex Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Enrollment would not have been met prior to the end of the pneumonia season. Termination is based on slow enrollment and not related to safety or efficacy.
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198626, "Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01198626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*